2 results
Approved WMOPending
To compare the effect of a 6-month of enriched care consisting of additional protein intake and regular resistance exercise on the prevalence of disproportional fat-free mass loss (defined as a FFML/WL>30% as main outcome parameter) in…
Approved WMORecruiting will start
To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen*s Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of…